# OnCo record biotheus (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/biotheus/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "biotheus" ;
  schema:name "Biotheus"@en ;
  schema:description "Biotheus was a Chinese antibody company that developed PM8002 (BNT327, pumitamig), an antibody that blocks both PD-L1 and VEGF-A. BioNTech, already its partner on the drug, bought the company in early 2025."@en ;
  schema:url <https://onco.cc/companies/biotheus/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1776985/000177698524000094/a99_1biontechtoacquirebiot.htm>, <https://www.sec.gov/Archives/edgar/data/1776985/000177698525000004/a99_1250131xbntxpressstate.htm> ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/pm8002/> .